Rome Therapeutics

Rome Therapeutics is a Cambridge, Massachusetts biotechnology company developing therapies that target the "repeatome" — the vast repetitive, non-coding regions of the human genome (the "dark genome," including LINE-1 and other transposable elements) implicated in cancer and autoimmune disease. Its discovery engine pairs ROMEMap, a proprietary high-resolution database of annotated functional repeats, with ROMEQuant, a machine-learning method for quantifying repeat expression and prioritizing targets and biomarkers. Backed by a16z and GV, the company raised a $77M Series B (2021) plus a $72M Series B extension to advance its lead program into clinical development. These are internal research/data-science tools; the company publishes no public developer or web API. This profile was surfaced as a VC portfolio lead and enriched by the pipeline.

Rome Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Genomics, Drug Discovery, and Oncology.

Rome Therapeutics’ developer surface includes engineering blog and 2 more developer resources.

🌐 Visit website 📡 Source on GitHub
8.1/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5
0 APIs
CompanyBiotechnologyGenomicsDrug DiscoveryOncologyAutoimmuneLife SciencesRepeatome

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5
Composite quality — 8.1/100 · minimal
Contract Quality 0.0 / 25
Developer Ergonomics 0.4 / 20
Commercial Clarity 0.0 / 20
Operational Transparency 0.0 / 13
Governance 0.0 / 12
Discoverability 6.8 / 10
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 15
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/rome-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Rome Therapeutics Domain Security

no transport/DNS hardening detected

SECURITY

Resources

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Company 2

The organization behind the API

Website
Website
 Blog
Blog

Source (apis.yml)

apis.yml Raw ↑ 
aid: rome-therapeutics
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/rome-therapeutics.png
name: Rome Therapeutics
description: Rome Therapeutics is a Cambridge, Massachusetts biotechnology company developing therapies that target the "repeatome"
  — the vast repetitive, non-coding regions of the human genome (the "dark genome," including LINE-1 and other transposable
  elements) implicated in cancer and autoimmune disease. Its discovery engine pairs ROMEMap, a proprietary high-resolution
  database of annotated functional repeats, with ROMEQuant, a machine-learning method for quantifying repeat expression and
  prioritizing targets and biomarkers. Backed by a16z and GV, the company raised a $77M Series B (2021) plus a $72M Series
  B extension to advance its lead program into clinical development. These are internal research/data-science tools; the company
  publishes no public developer or web API. This profile was surfaced as a VC portfolio lead and enriched by the pipeline.
url: https://raw.githubusercontent.com/api-evangelist/rome-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- a16z
- gv
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-21'
tags:
- Company
- Biotechnology
- Genomics
- Drug Discovery
- Oncology
- Autoimmune
- Life Sciences
- Repeatome
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/rome-therapeutics-domain-security.yml
- type: Website
  url: https://rometx.com
- type: Blog
  url: https://rometx.com/press-releases/
x-enrichment:
  date: '2026-07-21'
  status: minimal
  artifacts_added: 1
  pass: local-v1